HALOPROGIN
SMILES | Clc1cc(Cl)c(OCC#CI)cc1Cl |
InChIKey | CTETYYAZBPJBHE-UHFFFAOYSA-N |
Chemical properties
Hydrogen bond acceptors | 1 |
Hydrogen bond donors | 0 |
Rotatable bonds | 2 |
Molecular weight (Da) | 359.8 |
Drug properties
Molecular type | Small molecule |
Physiological/Surrogate | Surrogate |
Approved drug | No |
Database connections
Bioactivities
Receptor | Activity | Source | |||||||
---|---|---|---|---|---|---|---|---|---|
GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
NK2 | NK2R | Human | Tachykinin | A | pKi | 6.31 | 6.31 | 6.31 | ChEMBL |
α2B | ADA2B | Human | Adrenoceptors | A | pKi | 6.6 | 6.6 | 6.6 | ChEMBL |
α2C | ADA2C | Human | Adrenoceptors | A | pKi | 6.23 | 6.23 | 6.23 | ChEMBL |
α2A | ADA2A | Human | Adrenoceptors | A | pKi | 6.34 | 6.34 | 6.34 | ChEMBL |
D1 | DRD1 | Human | Dopamine | A | pKi | 6.55 | 6.55 | 6.55 | ChEMBL |
5-HT6 | 5HT6R | Human | 5-Hydroxytryptamine | A | pKi | 5.73 | 5.73 | 5.73 | ChEMBL |
5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pKi | 5.87 | 5.87 | 5.87 | ChEMBL |
D3 | DRD3 | Human | Dopamine | A | pKi | 6.78 | 6.78 | 6.78 | ChEMBL |
5-HT2A | 5HT2A | Human | 5-Hydroxytryptamine | A | pKi | 6.16 | 6.16 | 6.16 | ChEMBL |
A3 | AA3R | Human | Adenosine | A | pKi | 6.9 | 6.9 | 6.9 | ChEMBL |
κ | OPRK | Human | Opioid | A | pKi | 6.34 | 6.34 | 6.34 | ChEMBL |
5-HT2A | 5HT2A | Human | 5-Hydroxytryptamine | A | pKi | 8.21 | 8.21 | 8.21 | Drug Central |
5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pKi | 8.23 | 8.23 | 8.23 | Drug Central |
5-HT6 | 5HT6R | Human | 5-Hydroxytryptamine | A | pKi | 8.24 | 8.24 | 8.24 | Drug Central |
α2A | ADA2A | Human | Adrenoceptors | A | pKi | 8.2 | 8.2 | 8.2 | Drug Central |
α2B | ADA2B | Human | Adrenoceptors | A | pKi | 8.18 | 8.18 | 8.18 | Drug Central |
α2C | ADA2C | Human | Adrenoceptors | A | pKi | 8.21 | 8.21 | 8.21 | Drug Central |
D1 | DRD1 | Human | Dopamine | A | pKi | 8.18 | 8.18 | 8.18 | Drug Central |
D3 | DRD3 | Human | Dopamine | A | pKi | 8.17 | 8.17 | 8.17 | Drug Central |
κ | OPRK | Human | Opioid | A | pKi | 8.2 | 8.2 | 8.2 | Drug Central |
NK2 | NK2R | Human | Tachykinin | A | pKi | 8.2 | 8.2 | 8.2 | Drug Central |
A3 | AA3R | Human | Adenosine | A | pKi | 8.16 | 8.16 | 8.16 | Drug Central |
Receptor | Activity | Source | |||||||
---|---|---|---|---|---|---|---|---|---|
GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
NK2 | NK2R | Human | Tachykinin | A | pIC50 | 5.83 | 5.83 | 5.83 | ChEMBL |
α2B | ADA2B | Human | Adrenoceptors | A | pIC50 | 6.26 | 6.26 | 6.26 | ChEMBL |
α2C | ADA2C | Human | Adrenoceptors | A | pIC50 | 5.39 | 5.39 | 5.39 | ChEMBL |
α2A | ADA2A | Human | Adrenoceptors | A | pIC50 | 5.91 | 5.91 | 5.91 | ChEMBL |
D1 | DRD1 | Human | Dopamine | A | pIC50 | 6.25 | 6.25 | 6.25 | ChEMBL |
5-HT6 | 5HT6R | Human | 5-Hydroxytryptamine | A | pIC50 | 5.4 | 5.4 | 5.4 | ChEMBL |
5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pIC50 | 5.58 | 5.58 | 5.58 | ChEMBL |
D3 | DRD3 | Human | Dopamine | A | pIC50 | 6.31 | 6.31 | 6.31 | ChEMBL |
5-HT2A | 5HT2A | Human | 5-Hydroxytryptamine | A | pIC50 | 5.62 | 5.62 | 5.62 | ChEMBL |
A3 | AA3R | Human | Adenosine | A | pIC50 | 6.65 | 6.65 | 6.65 | ChEMBL |
κ | OPRK | Human | Opioid | A | pIC50 | 5.94 | 5.94 | 5.94 | ChEMBL |